I sent an email to Investor Relations last week wishing to clarify at what stage the review was at (as this was unclear from the 7 Aug announcement) - queries from investors could've been a factor.
Ann: FDA Strategy and Regulatory Update, page-15
Add TRI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $11.47M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 175000 | 2.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.8¢ | 212000 | 1 |
View Market Depth
| Last trade - 09.51am 16/05/2024 (20 minute delay) ? |
| TRI (ASX) Chart |
Day chart unavailable